https://www.selleckchem.com/products/brd-6929.html
Except for the minority of patients with targetable driver mutations, HMAs - likely as part of combination therapies - will remain the backbone of frontline MDS treatment. However, the wider use of genetic testing may enable a more targeted and individualized therapy of MDS patients.Uveal melanoma is a rare disease. Up to 50% of the patients will develop metastases for which the treatment options are limited. No randomized controlled data for the treatment of uveal melanoma patients are available. In this study we describe the clinical
Like
Comment
Share